SCA
SUPN icon

Snowden Capital Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Snowden Capital Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-25
Closed – – 1944
2021
Q4 		$0 Buy
+25
New +$758 ﹤0.01% 2146

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Snowden Capital Advisors's SUPN Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q1 2022, closing a stake of 25 shares.

Snowden Capital Advisors first reported a position in SUPN in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 230 funds tracked by Wall St. Rank hold SUPN as of Q1 2022.

  • Snowden Capital Advisors reported no remaining Supernus Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Snowden Capital Advisors sold 25 Supernus Pharmaceuticals shares in Q1 2022.
  • Snowden Capital Advisors first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Snowden Capital Advisors's Supernus Pharmaceuticals position peaked at $0 in Q4 2021.
  • 230 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.